DIA DiaSorin S.p.A.
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.…
Industry Peers
Diagnostics & ResearchKey Statistics
About DiaSorin (BIT: DIA)
›
DiaSorin (BIT: DIA) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 3,212 employees.
The shares were at 79.42 EUR on 19 November 2026, up 34.8% over 52 weeks. Its 52-week range is 52.34 EUR to 85.82 EUR: the price is 7.5% below the high and 51.7% above the low.
At a market capitalisation of 3.91B EUR, it trades at 29.2 times trailing earnings and 18.2 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 18% for DIA. It pays a dividend yielding 1.59% (it pays out 48% of its earnings), against a median of 0.73% among the dividend payers in that peer group.
DiaSorin reports return on equity of 9.8%, an operating margin of 22.3% and revenue up 10.0% year over year.
Its debt exceeds its cash by 673.40M EUR, a debt-to-equity ratio of 0.50. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Hold; their mean price target of 79.63 EUR is 0.3% above the current price. The next earnings report is expected on 26 March 2027.